CAJ | 학술논문

目的：探讨重组组织型纤溶酶原激活剂（ rt-PA）静脉溶栓治疗急性脑梗死的临床效果及安全性。方法选择发病在4．5h内，平均2．86±0．8h内急性脑梗死患者73例，分为两组，溶栓组50例患者给予rt-PA 0．9mg· kg-1· d-1静脉溶栓，常规治疗组23例患者采用抗血小板聚集药物等治疗，比较溶栓和常规治疗后24h、7d及14d美国国立卫生研究院卒中量表（ NIHSS）评分并记录不良反应。结果溶栓组治疗后24 h、7d及14d时，NIHSS评分较溶栓前及对照组均明显减少，差异有统计学意义（ P＜0．05）；溶栓后头颅MRI/CT及临床表现提示未出现症状性脑出血。结论 rt-PA静脉溶栓治疗发病4．5h内脑梗死是安全有效的。
목적：탐토중조조직형섬용매원격활제（ rt-PA）정맥용전치료급성뇌경사적림상효과급안전성。방법선택발병재4．5h내，평균2．86±0．8h내급성뇌경사환자73례，분위량조，용전조50례환자급여rt-PA 0．9mg· kg-1· d-1정맥용전，상규치료조23례환자채용항혈소판취집약물등치료，비교용전화상규치료후24h、7d급14d미국국립위생연구원졸중량표（ NIHSS）평분병기록불량반응。결과용전조치료후24 h、7d급14d시，NIHSS평분교용전전급대조조균명현감소，차이유통계학의의（ P＜0．05）；용전후두로MRI/CT급림상표현제시미출현증상성뇌출혈。결론 rt-PA정맥용전치료발병4．5h내뇌경사시안전유효적。
Objective To explore the clinical efficiency and safety of recombinant tissue plasminogen activator ( rt-PA) intravenous thrombolysis for patients with acute cerebral infarction .Methods Choose within 4.5 h ( average 28.6±0 .8) h of the patients with acute cerebral infarction 73 cases, they were divided into thrombolytic treatment group and routine treatment group , Thrombolysis group was given rt -PA 0.9 · kg-1 · d-1 intravenous thrombolysis , routine treatment group used the conventional treatments such as antiplatelet aggregation .The National Institutes of Health Stroke Scale (NIHSS)score were compared before and after treatment of 24 hours,7 days and 14 days, and record adverse reactions .Results Thrombolysis therapy after 24 h, 7 d and 14 d, NIHSS scores were significantly reduced than before thrombolysis and the control group , there were significant differences ( P<0.05);There was not appear symptomatic cerebral hemorrhage by cranial MRI /CT and clinical manifestations of prompt after thrombolysis.Conclusion rt-PA intravenous thrombolysis treatment within 4.5 h of the cerebral infarction is safe and effective.